A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study (Q37575167)
Jump to navigation
Jump to search
scientific article published on 31 October 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study |
scientific article published on 31 October 2016 |
Statements
1 reference
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study (English)
1 reference
Matthias W Beckmann
1 reference
Steffen Saupe
1 reference
Elke Jäger
1 reference
Marcus Schmidt
1 reference
Rolf Kreienberg
1 reference
Lothar Müller
1 reference
Burkhard Joerg Otremba
1 reference
Dirk Waldenmaier
1 reference
Julia Dorn
1 reference
Mathias Warm
1 reference
Michael Scholz
1 reference
Maike de Wit
1 reference
Jana Barinoff
1 reference
Hans-Joachim Lück
1 reference
Philipp Harter
1 reference
Doris Augustin
1 reference
Paul Harnett
1 reference
Salah-Eddin Al-Batran
1 reference
PELICAN Investigators
1 reference
1 reference
31 October 2016
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference